Exploiting mitochondrial apoptosis for the treatment of cancer

Mitochondrion

Volumn 10, Issue 6, 2010, Pages 598-603

  Fulda, Simone ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Apoptosis; Bcl 2 proteins; Cancer; Mitochondria

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; ADENINE NUCLEOTIDE TRANSLOCASE; ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE CITRATE LYASE; ALPHA TOCOPHEROL SUCCINATE; ANTINEOPLASTIC AGENT; ANTIOXIDANT; ATN 224; BETULIC ACID; DEOXYGLUCOSE; DICHLOROACETIC ACID; GLUTATHIONE; GOSSYPOL; ISOSORBIDE; LONIDAMINE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; MITOCHONDRIAL PROTEIN; OBATOCLAX; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN BID; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; RESVERATROL; RITUXIMAB; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; CANCER CELL; CELL METABOLISM; CHRONIC LYMPHATIC LEUKEMIA; DRUG TARGETING; GLIOBLASTOMA; GLYCOLYSIS; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG SMALL CELL CANCER; LYMPHOMA; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FAMILY; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; TUMOR CELL DESTRUCTION; WARBURG EFFECT;

ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; MITOCHONDRIA; NEOPLASMS;

EID: 78149359030     PISSN: 15677249     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mito.2010.05.001     Document Type: Review

References (91)

1. Adams J.M., Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26:1324-1337.
2. Alexandre J., Nicco C., Chereau C., Laurent A., Weill B., Goldwasser F., Batteux F. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J. Natl. Cancer Inst. 2006, 98:236-244.
3. Andre N., Carre M., Brasseur G., Pourroy B., Kovacic H., Briand C., Braguer D. Paclitaxel targets mitochondria upstream of caspase activation in intact human neuroblastoma cells. FEBS Lett. 2002, 532:256-260.
4. Azmi A.S., Mohammad R.M. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J. Cell Physiol. 2009, 218:13-21.
5. Belzacq A.S., El Hamel C., Vieira H.L., Cohen I., Haouzi D., Metivier D., Marchetti P., Brenner C., Kroemer G. Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437. Oncogene 2001, 20:7579-7587.
6. Bey E.A., Bentle M.S., Reinicke K.E., Dong Y., Yang C.R., Girard L., Minna J.D., Bornmann W.G., Gao J., Boothman D.A. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone. Proc. Natl. Acad. Sci. USA 2007, 104:11832-11837.
7. Biasutto L., Mattarei A., Marotta E., Bradaschia A., Sassi N., Garbisa S., Zoratti M., Paradisi C. Development of mitochondria-targeted derivatives of resveratrol. Bioorg. Med. Chem. Lett. 2008, 18:5594-5597.
8. Bonnet S., Archer S.L., Allalunis-Turner J., Haromy A., Beaulieu C., Thompson R., Lee C.T., Lopaschuk G.D., Puttagunta L., Harry G., Hashimoto K., Porter C.J., Andrade M.A., Thebaud B., Michelakis E.D. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007, 11:37-51.
9. Bouchier-Hayes L., Munoz-Pinedo C., Connell S., Green D.R. Measuring apoptosis at the single cell level. Methods 2008, 44:222-228.
10. Chipuk J.E., Bouchier-Hayes L., Green D.R. Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death Differ. 2006, 13:1396-1402.
11. Cipolat S., Rudka T., Hartmann D., Costa V., Serneels L., Craessaerts K., Metzger K., Frezza C., Annaert W., D'Adamio L., Derks C., Dejaegere T., Pellegrini L., D'Hooge R., Scorrano L., De Strooper B. Mitochondrial rhomboid PARL regulates cytochrome c release during apoptosis via OPA1-dependent cristae remodeling. Cell 2006, 126:163-175.
12. Constantinou C., Papas A., Constantinou A.I. Vitamin E and cancer: an insight into the anticancer activities of vitamin E isomers and analogs. Int. J. Cancer 2008, 123:739-752.
13. Costantini P., Belzacq A.S., Vieira H.L., Larochette N., de Pablo M.A., Zamzami N., Susin S.A., Brenner C., Kroemer G. Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis. Oncogene 2000, 19:307-314.
14. Cragg M.S., Kuroda J., Puthalakath H., Huang D.C., Strasser A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med. 2007, 4:1681-1689. (Discussion 1690).
15. Cragg M.S., Jansen E.S., Cook M., Harris C., Strasser A., Scott C.L. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J. Clin. Invest. 2008, 118:3651-3659.
16. Decaudin D., Castedo M., Nemati F., Beurdeley-Thomas A., De Pinieux G., Caron A., Pouillart P., Wijdenes J., Rouillard D., Kroemer G., Poupon M.F. Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo. Cancer Res. 2002, 62:1388-1393.
17. Degterev A., Boyce M., Yuan J. A decade of caspases. Oncogene 2003, 22:8543-8567.
18. Don A.S., Kisker O., Dilda P., Donoghue N., Zhao X., Decollogne S., Creighton B., Flynn E., Folkman J., Hogg P.J. A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 2003, 3:497-509.
19. Dong L.F., Swettenham E., Eliasson J., Wang X.F., Gold M., Medunic Y., Stantic M., Low P., Prochazka L., Witting P.K., Turanek J., Akporiaye E.T., Ralph S.J., Neuzil J. Vitamin E analogues inhibit angiogenesis by selective induction of apoptosis in proliferating endothelial cells: the role of oxidative stress. Cancer Res. 2007, 67:11906-11913.
20. Dong L.F., Low P., Dyason J.C., Wang X.F., Prochazka L., Witting P.K., Freeman R., Swettenham E., Valis K., Liu J., Zobalova R., Turanek J., Spitz D.R., Domann F.E., Scheffler I.E., Ralph S.J., Neuzil J. Alpha-tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II. Oncogene 2008, 27:4324-4335.
21. Dragovich T., Gordon M., Mendelson D., Wong L., Modiano M., Chow H.H., Samulitis B., O'Day S., Grenier K., Hersh E., Dorr R. Phase I trial of imexon in patients with advanced malignancy. J. Clin. Oncol. 2007, 25:1779-1784.
22. Frezza C., Cipolat S., Martins de Brito O., Micaroni M., Beznoussenko G.V., Rudka T., Bartoli D., Polishuck R.S., Danial N.N., De Strooper B., Scorrano L. OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell 2006, 126:177-189.
23. Fulda S. Tumor resistance to apoptosis. Int. J. Cancer 2009, 124:511-515.
24. Fulda S., Debatin K.M. Betulinic acid induces apoptosis through a direct effect on mitochondria in neuroectodermal tumors. Med. Pediatr. Oncol. 2000, 35:616-618.
25. Fulda S., Debatin K.M. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006, 25:4798-4811.
26. Fulda S., Friesen C., Los M., Scaffidi C., Mier W., Benedict M., Nunez G., Krammer P.H., Peter M.E., Debatin K.M. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res. 1997, 57:4956-4964.
27. Fulda S., Scaffidi C., Susin S.A., Krammer P.H., Kroemer G., Peter M.E., Debatin K.M. Activation of mitochondria and release of mitochondrial apoptogenic factors by betulinic acid. J. Biol. Chem. 1998, 273:33942-33948.
28. Fulda S., Susin S.A., Kroemer G., Debatin K.M. Molecular ordering of apoptosis induced by anticancer drugs in neuroblastoma cells. Cancer Res. 1998, 58:4453-4460.
29. Gatenby R.A., Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat. Rev. Cancer 2004, 4:891-899.
30. Gledhill J.R., Montgomery M.G., Leslie A.G., Walker J.E. Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc. Natl. Acad. Sci. USA 2007, 104:13632-13637.
31. Gogvadze V., Orrenius S., Zhivotovsky B. Mitochondria in cancer cells: what is so special about them?. Trends Cell Biol. 2008, 18:165-173.
32. Goldin N., Arzoine L., Heyfets A., Israelson A., Zaslavsky Z., Bravman T., Bronner V., Notcovich A., Shoshan-Barmatz V., Flescher E. Methyl jasmonate binds to and detaches mitochondria-bound hexokinase. Oncogene 2008, 27:4636-4643.
33. Gong Y., Somwar R., Politi K., Balak M., Chmielecki J., Jiang X., Pao W. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med 2007, 4:e294.
34. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
35. Hann C.L., Daniel V.C., Sugar E.A., Dobromilskaya I., Murphy S.C., Cope L., Lin X., Hierman J.S., Wilburn D.L., Watkins D.N., Rudin C.M. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res. 2008, 68:2321-2328.
36. Hatzivassiliou G., Zhao F., Bauer D.E., Andreadis C., Shaw A.N., Dhanak D., Hingorani S.R., Tuveson D.A., Thompson C.B. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005, 8:311-321.
37. Huang S., Sinicrope F.A. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells. Cancer Res. 2008, 68:2944-2951.
38. Huang P., Feng L., Oldham E.A., Keating M.J., Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000, 407:390-395.
39. 2-mediated oxidation and inactivation of phosphatases in growth factor signaling. Proc. Natl. Acad. Sci. USA 2008, 105:7147-7152.
40. Kang M.H., Kang Y.H., Szymanska B., Wilczynska-Kalak U., Sheard M.A., Harned T.M., Lock R.B., Reynolds C.P. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 2007, 110:2057-2066.
41. Kitada S., Leone M., Sareth S., Zhai D., Reed J.C., Pellecchia M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J. Med. Chem. 2003, 46:4259-4264.
42. Kitada S., Kress C.L., Krajewska M., Jia L., Pellecchia M., Reed J.C. Bcl-2 antagonist apogossypol (NSC736630) displays single-agent activity in Bcl-2-transgenic mice and has superior efficacy with less toxicity compared with gossypol (NSC19048). Blood 2008, 111:3211-3219.
43. Kohl T.M., Hellinger C., Ahmed F., Buske C., Hiddemann W., Bohlander S.K., Spiekermann K. BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia 2007, 21:1763-1772.
44. Konopleva M., Contractor R., Tsao T., Samudio I., Ruvolo P.P., Kitada S., Deng X., Zhai D., Shi Y.-X., Sneed T., Verhaegen M., Soengas M., Ruvolo V.R., McQueen T., Schober W.D., Watt J.C., Jiffar T., Ling X., Marini F.C., Harris D., Dietrich M., Estrov Z., McCubrey J., May W.S., Reed J.C., Andreeff M. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006, 10:375-388.
45. Kroemer G., Galluzzi L., Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 2007, 87:99-163.
46. Kuroda J., Puthalakath H., Cragg M.S., Kelly P.N., Bouillet P., Huang D.C.S., Kimura S., Ottmann O.G., Druker B.J., Villunger A., Roberts A.W., Strasser A. Bim and bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc. Natl. Acad. Sci. USA 2006, 103:14907-14912.
47. Kuroda J., Kimura S., Strasser A., Andreeff M., O'Reilly L.A., Ashihara E., Kamitsuji Y., Yokota A., Kawata E., Takeuchi M., Tanaka R., Tabe Y., Taniwaki M., Maekawa T. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ. 2007, 14:1667-1677.
48. Kutuk O., Letai A. Alteration of the mitochondrial apoptotic pathway is key to acquired paclitaxel resistance and can be reversed by ABT-737. Cancer Res. 2008, 68:7985-7994.
49. Kuwana T., Mackey M.R., Perkins G., Ellisman M.H., Latterich M., Schneiter R., Green D.R., Newmeyer D.D. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 2002, 111:331-342.
50. Lehenkari P.P., Kellinsalmi M., Napankangas J.P., Ylitalo K.V., Monkkonen J., Rogers M.J., Azhayev A., Vaananen H.K., Hassinen I.E. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol. Pharmacol. 2002, 61:1255-1262.
51. Liby K.T., Yore M.M., Sporn M.B. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat. Rev. Cancer 2007, 7:357-369.
52. Liu G., Kelly W.K., Wilding G., Leopold L., Brill K., Somer B. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin. Cancer Res. 2009, 15:3172-3176.
53. Lu J., Chew E.H., Holmgren A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc. Natl. Acad. Sci. USA 2007, 104:12288-12293.
54. Lynn A., Jones L. Gossypol and some other terpenoids, flavonoids, and phenols that affect quality of cottonseed protein. Am. Oil Chem. Soc. 1979, 56:727-730.
55. Maeda H., Hori S., Ohizumi H., Segawa T., Kakehi Y., Ogawa O., Kakizuka A. Effective treatment of advanced solid tumors by the combination of arsenic trioxide and L-buthionine-sulfoximine. Cell Death Differ. 2004, 11:737-746.
56. Majewski N., Nogueira V., Bhaskar P., Coy P.E., Skeen J.E., Gottlob K., Chandel N.S., Thompson C.B., Robey R.B., Hay N. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol. Cell 2004, 16:819-830.
57. Marchetti P., Zamzami N., Joseph B., Schraen-Maschke S., Mereau-Richard C., Costantini P., Metivier D., Susin S.A., Kroemer G., Formstecher P. The novel retinoid 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. Cancer Res. 1999, 59:6257-6266.
58. Mason K.D., Khaw S.L., Rayeroux K.C., Chew E., Lee E.F., Fairlie W.D., Grigg A.P., Seymour J.F., Szer J., Huang D.C., Roberts A.W. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia 2009, 23:2034-2041.
59. Mason K.D., Carpinelli M.R., Fletcher J.I., Collinge J.E., Hilton A.A., Ellis S., Kelly P.N., Ekert P.G., Metcalf D., Roberts A.W., Huang D.C.S., Kile B.T. Programmed a nuclear cell death delimits platelet life span. Cell 2007, 128:1173-1186.
60. Mason K.D., Vandenberg C.J., Scott C.L., Wei A.H., Cory S., Huang D.C., Roberts A.W. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc. Natl. Acad. Sci. USA 2008, 105:17961-17966.
61. Meng R.D., El-Deiry W.S. P53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma. Exp. Cell Res. 2001, 262:154-169.
62. Miller L.A., Goldstein N.B., Johannes W.U., Walton C.H., Fujita M., Norris D.A., Shellman Y.G. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. J. Invest. Dermatol. 2009, 129:964-971.
63. Nakagawa T., Shimizu S., Watanabe T., Yamaguchi O., Otsu K., Yamagata H., Inohara H., Kubo T., Tsujimoto Y. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 2005, 434:652-658.
64. Nguyen M., Marcellus R.C., Roulston A., Watson M., Serfass L., Murthy Madiraju S.R., Goulet D., Viallet J., Belec L., Billot X., Acoca S., Purisima E., Wiegmans A., Cluse L., Johnstone R.W., Beauparlant P., Shore G.C. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl. Acad. Sci. USA 2007, 104:19512-19517.
65. Notario B., Zamora M., Vinas O., Mampel T. All-trans-retinoic acid binds to and inhibits adenine nucleotide translocase and induces mitochondrial permeability transition. Mol. Pharmacol. 2003, 63:224-231.
66. O'Brien S.M., Claxton D.F., Crump M., Faderl S., Kipps T., Keating M.J., Viallet J., Cheson B.D. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 2009, 113:299-305.
67. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., Joseph M.K., Kitada S., Korsmeyer S.J., Kunzer A.R., Letai A., Li C., Mitten M.J., Nettesheim D.G., Ng S., Nimmer P.M., O'Connor J.M., Oleksijew A., Petros A.M., Reed J.C., Shen W., Tahir S.K., Thompson C.B., Tomaselli K.J., Wang B., Wendt M.D., Zhang H., Fesik S.W., Rosenberg S.H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
68. Oudard S., Carpentier A., Banu E., Fauchon F., Celerier D., Poupon M.F., Dutrillaux B., Andrieu J.M., Delattre J.Y. Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J. Neurooncol. 2003, 63:81-86.
69. Palmeira C.M., Wallace K.B. Benzoquinone inhibits the voltage-dependent induction of the mitochondrial permeability transition caused by redox-cycling naphthoquinones. Toxicol. Appl. Pharmacol. 1997, 143:338-347.
70. Paoluzzi L., Gonen M., Bhagat G., Furman R.R., Gardner J.R., Scotto L., Gueorguiev V.D., Heaney M.L., Manova K., O'Connor O.A. The BH3-only mimetic ABT-737 synergizes the anti-neoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 2008, 112:2906-2916.
71. Perez-Galan P., Roue G., Villamor N., Campo E., Colomer D. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood 2007, 109:4441-4449.
72. Petronilli V., Costantini P., Scorrano L., Colonna R., Passamonti S., Bernardi P. The voltage sensor of the mitochondrial permeability transition pore is tuned by the oxidation-reduction state of vicinal thiols. Increase of the gating potential by oxidants and its reversal by reducing agents. J. Biol. Chem. 1994, 269:16638-16642.
73. Roberts A.W., Wilson W., Gandhi L., O'Connor O.A., Rudin C.M., Brown J.R., Xiong H., Chiu Y., Enschede S., Krivoshik A.P. Ongoing phase I studies of ABT-263: mitigating Bcl-XL induced thrombocytopenia with lead-in and continuous dosing. J. Clin. Oncol. 2009, 27:3505. (Meeting Abstracts).
74. Salti G.I., Kichina J.V., Das Gupta T.K., Uddin S., Bratescu L., Pezzuto J.M., Mehta R.G., Constantinou A.I. Betulinic acid reduces ultraviolet-C-induced DNA breakage in congenital melanocytic naeval cells: evidence for a potential role as a chemopreventive agent. Melanoma Res. 2001, 11:99-104.
75. Schimmer A.D., O'Brien S., Kantarjian H., Brandwein J., Cheson B.D., Minden M.D., Yee K., Ravandi F., Giles F., Schuh A., Gupta V., Andreeff M., Koller C., Chang H., Kamel-Reid S., Berger M., Viallet J., Borthakur G. A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. Clin. Cancer Res. 2008, 14:8295-8301.
76. Selzer E., Pimentel E., Wacheck V., Schlegel W., Pehamberger H., Jansen B., Kodym R. Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. J. Invest. Dermatol. 2000, 114:935-940.
77. Selzer E., Thallinger C., Hoeller C., Oberkleiner P., Wacheck V., Pehamberger H., Jansen B. Betulinic acid-induced Mcl-1 expression in human melanoma-mode of action and functional significance. Mol. Med. 2002, 8:877-884.
78. Simons A.L., Ahmad I.M., Mattson D.M., Dornfeld K.J., Spitz D.R. 2-Deoxy-d-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res. 2007, 67:3364-3370.
79. Song J.H., Kandasamy K., Kraft A.S. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J. Biol. Chem. 2008, 283:25003-25013.
80. Tagscherer K.E., Fassl A., Campos B., Farhadi M., Kraemer A., Bock B.C., Macher-Goeppinger S., Radlwimmer B., Wiestler O.D., Herold-Mende C., Roth W. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 2008, 27:6646-6656.
81. Thurnher D., Turhani D., Pelzmann M., Wannemacher B., Knerer B., Formanek M., Wacheck V., Selzer E. Betulinic acid: a new cytotoxic compound against malignant head and neck cancer cells. Head Neck 2003, 25:732-740.
82. Trachootham D., Zhou Y., Zhang H., Demizu Y., Chen Z., Pelicano H., Chiao P.J., Achanta G., Arlinghaus R.B., Liu J., Huang P. Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 2006, 10:241-252.
83. Trudel S., Li Z.H., Rauw J., Tiedemann R.E., Wen X.Y., Stewart A.K. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Blood 2007, 109:5430-5438.
84. Tse C., Shoemaker A.R., Adickes J., Anderson M.G., Chen J., Jin S., Johnson E.F., Marsh K.C., Mitten M.J., Nimmer P., Roberts L., Tahir S.K., Xiao Y., Yang X., Zhang H., Fesik S., Rosenberg S.H., Elmore S.W. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res. 2008, 68:3421-3428.
85. Van Delft M.F., Wei A.H., Mason K.D., Vandenberg C.J., Chen L., Czabotar P.E., Willis S.N., Scott C.L., Day C.L., Cory S., Adams J.M., Roberts A.W., Huang D.C.S. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006, 10:389-399.
86. Warburg O., Posener K., Negelein E. Über den Stoffwechsel der Tumoren. Biochemische Zeitschrift 1924, 152:319-344.
87. Whitecross K.F., Alsop A.E., Cluse L.A., Wiegmans A., Banks K.M., Coomans C., Peart M.J., Newbold A., Lindemann R.K., Johnstone R.W. Defining the target specificity of ABT-737 and synergistic antitumor activities in combination with histone deacetylase inhibitors. Blood 2009, 113:1982-1991.
88. Wick W., Grimmel C., Wagenknecht B., Dichgans J., Weller M. Betulinic acid-induced apoptosis in glioma cells: a sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. J. Pharmacol. Exp. Ther. 1999, 289:1306-1312.
89. Xiao D., Lew K.L., Zeng Y., Xiao H., Marynowski S.W., Dhir R., Singh S.V. Phenethyl isothiocyanate-induced apoptosis in PC-3 human prostate cancer cells is mediated by reactive oxygen species-dependent disruption of the mitochondrial membrane potential. Carcinogenesis 2006, 27:2223-2234.
90. Zhang H., Nimmer P.M., Tahir S.K., Chen J., Fryer R.M., Hahn K.R., Iciek L.A., Morgan S.J., Nasarre M.C., Nelson R., Preusser L.C., Reinhart G.A., Smith M.L., Rosenberg S.H., Elmore S.W., Tse C. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ. 2007, 14:943-951.
91. Zuco V., Supino R., Righetti S.C., Cleris L., Marchesi E., Gambacorti-Passerini C., Formelli F. Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells. Cancer Lett. 2002, 175:17-25.